Sweden, April 16 -- The European Investment Bank (EIB) is lending €20 million to Swedish biotechnology company BioLamina to expand its development of laminin technologies enabling next-generation cell therapies and more advanced, animal-free methods for drug safety testing. Cell therapies can be used to target conditions such as type 1 diabetes, Parkinson's disease, heart failure, acute liver failure and cancer. Many of these conditions remain difficult to treat or have no cure.BioLamina will use the EIB financing to expand and scale up production of its laminins, unique proteins used to grow and maintain cells in laboratory environments. Developed through pioneering research by the company's founders, these proteins act as a foundati...